2024年2月25日 · Implement evidence-based practices for initiating and titrating PCSK9 inhibitors in eligible patients to achieve optimal low-density lipoprotein cholesterol reduction and cardiovascular risk management.

PCSK9 is a proprotein convertase which is involved in the degradation of low-density lipoprotein (LDL) receptors in the liver. Mutations in the PCSK9 gene cause familial hypercholesterolaemia in a subset of patients by reducing the number of LDL receptors on the surface of hepatocytes.

Antibodies to PCSK9 have been approved by regulatory agencies for the treatment of individuals with inadequately treated levels of LDL-cholesterol (LDL-C). They are capable of lowering LDL-C by an average of 60 percent in patients either with or without background statin therapy.

Two PCSK9 inhibitors are currently approved for use: alirocumab and evolocumab. Both are fully human monoclonal antibodies that bind free PCSK9. Herein we discuss the mechanism of action, efficacy, and safety of PCSK9 inhibitors. clinical problem.

2018年6月22日 · Currently, the only FDA‐approved PCSK9 inhibitors are 2 fully human monoclonal antibodies that bind extracellular PCSK9: alirocumab 20 and evolocumab, 21 administered via subcutaneous injections every 2 weeks (Q2W) or once monthly.

Current evidence shows reductions in LDL-C levels of up to 70 % may be achieved with PCSK9 inhibition, independent of background statin therapy. This review examines the most recent evidence and future prospects for the use of PCSK9 inhibitors in …

PCSK9 inhibition is capable of promoting a mean LDL reduction of up to 60%, with potential for very significant clinical repercussions, as every 38 mg/dL reduction in LDL appears to be associated with a 22% reduction in cardiovascular risk.

2018年1月29日 · This review discusses the history and mechanism of action of PCSK9 inhibitors, their metabolic effects, and clinical outcomes associated with these medications, highlighting recent large cardiovascular outcome trials investigating these therapies.

PCSK9 is a proprotein convertase which is involved in the degradation of low-density lipoprotein (LDL) receptors in the liver. Mutations in the PCSK9 gene cause familial hypercholesterolaemia in a subset of patients by reducing the number of LDL receptors on the surface of hepatocytes.

This review discusses the history and mechanism of action of PCSK9 inhibitors, their metabolic effects, and clinical outcomes associated with these medications, highlighting recent large cardiovascular outcome trials investigating these therapies.